Skip to Navigation

Smart Technologies, Making Medicines Better

PhaseBio Featured Technology

ELPylation™/InGel™ for Drug Delivery

Target and deliver your molecules to prolong half-life, reduce dosing frequency and limit toxicity

deltaPhase™ Purification Technology

Leverage the power of Elastin-Like Peptides (ELPs), novel biopolymers that offer significant improvements over traditional recombinant expression and purification

PhaseBio Pharmaceuticals - Revolutionary Developments

 PhaseBio Pharmaceuticals, Inc. (PhaseBioTM), located in Research Triangle Park, NC, is a development stage, privately held protein engineering company focused on developing the next generation of biopharmaceuticals. The company's versatile technology is based on biopolymers of elastin-like repeating subunits to which drugs can be attached or peptides and proteins genetically fused, enhancing the pharmacology and delivery of therapeutics.

The technology provides greatly improved efficiency in bio-manufacturing via improved expression and rapid purification (deltaPhaseTM), providing attractive Cost of Goods (COGs). 

  • PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding […]
  • Craig Rosen, Ph.D., Biopharmaceutical Development Expert, Joins Phase Bioscience, Inc. as Executive Chairman […]
  • Leading Protein Engineering Executive Joins Phase Bioscience as CEO […]
  • Phase Bioscience Secures Funding Resources and Laboratory Space […]
  • Phase Bioscience Announces Series B Investment from Johnson & Johnson... […]
  • Next-Generation Protein Therapeutics Sept. 9-11, 2008 Budapest, […]
  • BioProcess International Conference Recovery and Purification Track Sept. 23-26, 2008 Anaheim, CA […]
  • Early to Late Stage Bioprocess Development Summit Oct. 20-22, 2008  Boston, MA […]
  • 21st Annual Bioprocess Technology Seminars & Exhibition Nov. 10-14, 2008 Rio Grande, Puerto Rico […]
  • Current Trends in Dosage Form Development and Biologics Formulation  Jan. 11-16, 2009, San Diego, […]
  • Furgeson, D.Y., M.R. Dreher, and A. Chilkoti, Structural optimization of a "smart" doxorubicin-polypeptide […]
  • Meyer, D.E. and A. Chilkoti, Quantification of the effects of chain length and concentration on the thermal behavior of […]
  • Dreher, M.R., D. Raucher, N. Balu, O.M. Colvin, S.M. Ludeman, and A. Chilkoti, Evaluation of an elastin-like […]
  • Meyer, D.E. and A. Chilkoti, Genetically encoded synthesis of protein-based polymers with precisely specified molecular […]
  • Meyer, D.E., G.A. Kong, M.W. Dewhirst, M.R. Zalutsky, and A. Chilkoti, Targeting a genetically engineered elastin-like […]
PhaseBio Pharmaceuticals, Inc.
4020 Aerial Center Parkway, Suite 101
Morrisville, NC 27560
Phone: 919.535.8861 | Fax: 919.535.8867